New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis

Seminars in Arthritis and Rheumatism

Volumn 32, Issue 3 SUPPL. 1, 2002, Pages 4-14

  Hochberg, Marc C ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Coxibs; Nonsteroidal antiinflammatory drugs; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; ANALGESIA; CLINICAL TRIAL; CONSTIPATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPEPSIA; ENDOSCOPY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; LOW BACK PAIN; OSTEOARTHRITIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STOMACH ULCER;

EID: 0036932869     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2002.37215     Document Type: Review

References (46)

1. CDC. Prevalence of disabilities and associated health conditions among adults-United States. MMWR 2001;50:120-5.
2. Davies NM, Saleh JY, Skjodt NM. Detection and prevention of NSAID-induced enteropathy. J Pharm Pharm Sci 2000;3:137-55.
3. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
4. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999:50:661-7.
5. Riendeau D, Percival MD, Brideau C, Charleson S. Dube D, Ethier D, et al. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-66.
6. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24:799-802.
7. Bellamy N, Campbell J, Syrotuik J. Comparative study of self-rating pain scales in osteoarthritis patients. Curr Med Res Opin 1999;15:113-9.
8. Bellamy N, Clinical trials design: Structure modifying agents for osteoarthritis. Future guidelines: Areas for development. Osteoarthritis Cartilage 1999;7:424-6.
9. Bellamy N, Campbell J, Syrotuik J. Comparative study of self-rating pain scales in rheumatoid arthritis patients. Curr Med Res Opin 1999:15:121-7.
10. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-81.
11. Strand V. Hochberg MC. Design of and outcome measures for use in clinical trials in patients with osteoarthritis. In: Moskowitz RW, Howell DS, Altman RD, Buckwalter JA, Goldberg VM, Eds. Osteoarthritis, 3rd Ed. Philadelphia, PA: Saunders, 2001:636-49.
12. Simon L, Lanza F, Lipsky P. Hubbard R, Talwalker S. Schwartz B. et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998:41:1591-602.
13. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
14. McKenna F, Borenstein D. Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001:30:11-8.
15. Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001;23:213-27.
16. Singh G, Fort JL, Triadafilotoulos G, Bello AE. SUCCESS-1: A global osteoarthritis (OA) trial in 13,247 randomized patients. Celecoxib provides similar efficacy to diclofenac and naproxen while providing significantly improved UGI safety. Paper presented at: 65th Annual Scientific Meeting of the American College of Rheumatology; November 11-15. 2001; San Francisco, CA. Abstract 496.
17. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978-87.
18. Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. Arch Fam Med 2000;9:1124-34.
19. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
20. Scott L, Lamb H. Rofecoxib. Drugs 1999;58:499-507.
21. Detora LM, Krupa D, Bolognese J, Sperling RS, Ehrich EW. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. J Rheumatol 2001;28:2494-503.
22. FDA. Vioxx: Arthritis Advisory Committee Meeting, Gaithersburg. Md. http://www.fda.gov/ohrms/dockets/ac/01/slides/3677s2.htm 2001.
23. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10:290-6.
24. Goldman M, Schutzer S. Valdecoxib. Formulary 2002;37:68-77.
25. Fisher CA, Curtis SP, Resnick H, Ripley P, Leung AT, Ko AT, et al. Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks. Paper presented at: 65th Annual Scientific Meeting of the American College of Rheumatology; November 11-15, 2001; San Francisco, CA. Abstract 495.
26. Schnitzer TJ, Geusens P, Hasler P, Patel SK, Poor G, Senftleber I, et al. Efficacy and safety of COX189 in osteoarthritis: A multi-national study. Arthritis Rheum 2000;43(suppl): S336. Abstract 1616.
27. Novartis COX-189 TARGET study will assess CV safety of COX-2 inhibitor. The Pink Sheet. FDC Reports 2001 2001;63:32.
28. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
29. McKenna F, Weaver A, Fiechmer JJ, Bello AE, Fort JG. COX-2 specific inhibitors in the management of osteoarthritis of the knee: A placebo-controlled, randomized, double-blind study. J Clin Rheumatol 2001;7:151-9.
30. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: A randomized trial. JAMA 2002;287:64-71.
31. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
32. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 1999;282:1921-8.
33. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999;354:2106-11.
34. Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999;21:1688-702.
35. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8. 2 p following 8.
36. FDA AAC. Briefing Information: NDA 21-042/S007 Vioxx (Rofecoxib). Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/367762.htm Accessed 2001.
37. Truitt KE, Guesens PP, DeTora LM, Zhao PL, Kress B. Results of a pivotal (phase III) placebo and active comparator controlled efficacy trial of rofecoxib 25 and 50 mg in adult patients with rheumatoid arthritis (RA). Paper presented at: EULAR 2001; June 13-16, 2001; Prague, Czech Republic. Abstract FRI0037.
38. Truitt K, Lee M, DeTora L, Anderson M, Zhao PL. Results of a pivotal (phase III) placebo and active comparator controlled efficacy trial of rofecoxib 25 and 50 mg in adult patients with rheumatoid arthritis (RA). Paper presented at: 65th Annual Scientific Meeting of the American College of Rheumatology; November 11-15, 2001; San Francisco, CA. Abstract 1897.
39. Bensen W, Weaver A, Espinoza L, Riley W, Paperiello B, Recker DP. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis. Paper presented at: 65th Annual Scientific Meeting of the American College of Rheumatology; November 11-15, 2001; San Francisco, CA. Abstract 1896.
40. Melian A, Curtis S, Matsumoto A, Zhao PL, McCormick CL, Rodgers DB, et al. Etoricoxib in the treatment of rheumatoid arthritis: A 12-week, placebo-controlled and active-comparator, double-blind U.S. study. Paper presented at: 65th Annual Scientific Meeting of the American College of Rheumatology; November 11-15, 2001; San Francisco, CA. Abstract LB-7.
41. Katz N, Johnson K, Krupa D, WD J, Borenstein D. Rofecoxib in the treatment of chronic low back pain in two multicenter trials. Paper presented at: 20th Annual Meeting of the American Pain Society; April 19-22, 2001; Phoenix, AZ. Abstract 718.
42. Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med 2002;69(suppl 1):S131-9
43. Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med 2002;69(suppl 1)SI40.
44. American Pain Society. Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Arthritis, 2002.
45. Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 2002;46:328-46.
46. Guidelines for the management of osteoarthritis of the hip or knee. Arthritis Rheum 2000;43:1905-15.